Artiva Biotherapeutics, Inc. (ARTV) AI Stock Analysis

• Market Cap: $98.67M
• Dividend Yield: N/A
• Average Volume (3M): 185.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.40
• Revenue Growth: -100.00%
• EPS Growth: -17.10%
• Country: US
• Employees: 96
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.88
• Shares Outstanding: 24,544,905
• 10 Day Avg. Volume: 188,566
• 30 Day Avg. Volume: 185,569
• PEG Ratio: -0.01
• Price to Book (P/B): 1.32
• Price to Sales (P/S): 978.41
• P/FCF Ratio: -4.41
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $18.67
• Price Target Upside: 364.43% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -3.36
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: $4.50 ▲(11.94% Upside)

The score is held back primarily by collapsing revenue, persistent large losses, and escalating cash burn that increase financing risk. This is partially offset by strong recent technical trend/momentum and a positive clinical-trial update, while valuation remains constrained by negative earnings and no dividend signal.

Positive Factors

Allogeneic (off-the-shelf) NK platform

An allogeneic, off-the-shelf NK cell model is a durable strategic asset: it can enable scalable manufacturing and repeat dosing versus autologous approaches, broaden potential partner and payer interest, and support faster commercial rollout if clinical and regulatory milestones are met.

Positive AlloNK clinical data

Initial safety and translational signals materially reduce clinical and regulatory risk for the AlloNK program. Demonstrated outpatient feasibility and consistent biological effect strengthen the program's commercial thesis and support planned FDA interactions in 2026, improving long-term development prospects.

Low leverage and positive equity

Modest debt and a return to positive equity provide balance sheet flexibility relative to highly leveraged peers. This reduces near-term insolvency risk and supports the ability to raise funds or partner programs without the immediate pressure of high fixed financial obligations.

Negative Factors

Revenue collapse

A complete collapse of revenue and loss of operational scale materially weakens the company's ability to self-fund R&D and commercial activities. Absent new revenue streams, this elevates dependence on capital markets or partners and increases long-term execution risk.

Severe cash burn

High negative operating and free cash flow indicate substantial ongoing financing needs. Persistent cash burn shortens runway, increases dilution or covenant risk from financings, and constrains strategic optionality for clinical programs over the coming months.

Large persistent losses

Sustained, sizable net losses and negative returns on equity signal that profitability is distant. Continued losses limit reinvestment capacity, pressure cash reserves, and raise the probability of disruptive financing or program cutbacks absent milestone-based partnerships.

Artiva Biotherapeutics, Inc. Business Overview & Revenue Model

Company Description

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

How the Company Makes Money

Artiva Biotherapeutics generates revenue primarily through the development and commercialization of its cell therapy products. The company may secure funding through various channels, including equity financing, grants, and collaborations with larger pharmaceutical companies. Key revenue streams could include upfront payments, milestone payments, and royalties from partnerships and licensing agreements related to its NK cell therapy products. Additionally, Artiva could generate income through clinical trial collaborations and research agreements aimed at advancing its therapeutic candidates, as well as potential future sales of approved therapies once they enter the market.

Artiva Biotherapeutics, Inc. Financial Statement Overview

Summary

Fundamentals are very weak: revenue fell from $33.5M (2023) to $0.25M (2024) and is $0 in TTM, with large ongoing losses (TTM net loss ~$72.3M; EBIT ~$86.1M) and heavy cash burn (TTM operating cash flow ~-$76.7M; free cash flow ~-$78.9M). Balance sheet leverage is modest (TTM debt-to-equity ~0.09) and equity is positive in 2024/TTM, but historical negative equity and continued losses keep financial risk elevated.

Income Statement

Operating performance remains very weak. Revenue collapsed from $33.5M (2023) to $0.25M (2024) and is $0 in TTM (Trailing-Twelve-Months), indicating a sharp loss of scale. Losses are persistent and large (TTM net loss of ~$72.3M; EBIT of ~$86.1M), with profitability not yet stabilizing despite prior revenue growth in 2022–2023. Strength: the cost structure shows full gross profit in most years where revenue exists, but the business is overwhelmingly driven by operating expenses rather than gross margin.

Balance Sheet

Leverage is modest and improving on the latest view, with low debt relative to equity in TTM (Trailing-Twelve-Months) (debt-to-equity ~0.09; total debt ~$11.7M vs. equity ~$129.2M), which provides financial flexibility. However, equity has been volatile and was negative in 2020–2023 before turning positive in 2024 and remaining positive in TTM—an important risk signal about historical capital structure stability. Returns on equity are negative in 2024 and TTM, reflecting ongoing losses despite the healthier headline leverage.

Cash Flow

Cash burn is significant and ongoing. TTM (Trailing-Twelve-Months) operating cash flow is about -$76.7M and free cash flow about -$78.9M, worse than 2024 levels, implying rising cash consumption. A partial positive is that free cash flow has tracked net losses reasonably closely (free cash flow to net income ~1.03 in TTM), suggesting losses are largely translating into cash burn without major accounting offsets—still, the magnitude of outflows heightens financing risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	251.00K	33.49M	4.93M	2.00M	0.00
Gross Profit	-662.00K	251.00K	33.49M	4.93M	2.00M	0.00
EBITDA	-82.23M	-64.85M	-28.41M	-58.67M	-71.58M	-17.52M
Net Income	-72.31M	-58.49M	-27.70M	-58.39M	-71.83M	-17.99M
Balance Sheet
Total Assets	―	209.58M	105.11M	133.05M	169.93M	29.23M
Cash, Cash Equivalents and Short-Term Investments	―	185.43M	76.97M	102.53M	160.92M	25.44M
Total Debt	―	14.35M	16.91M	19.45M	1.74M	2.12M
Total Liabilities	―	22.94M	267.13M	273.75M	258.78M	50.80M
Stockholders Equity	―	186.64M	-162.01M	-140.70M	-88.86M	-21.57M
Cash Flow
Free Cash Flow	-78.91M	-55.67M	-50.69M	-57.13M	-17.03M	-13.82M
Operating Cash Flow	-76.67M	-55.03M	-47.43M	-50.83M	-15.30M	-13.54M
Investing Cash Flow	46.41M	-120.46M	-25.98M	-6.30M	-1.72M	-284.00K
Financing Cash Flow	100.00K	162.23M	24.39M	-1.26M	152.75M	37.40M

Artiva Biotherapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.02
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTV, the sentiment is Negative. The current price of 4.02 is below the 20-day moving average (MA) of 4.50, below the 50-day MA of 4.19, and above the 200-day MA of 3.09, indicating a neutral trend. The MACD of -0.07 indicates Positive momentum. The RSI at 41.61 is Neutral, neither overbought nor oversold. The STOCH value of 23.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARTV.

Artiva Biotherapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	57 Neutral	$114.24M	-1.56	-49.78%	―	-82.16%	14.58%
ARTV	56 Neutral	$98.67M	―	-47.96%	―	-100.00%	-17.10%
JSPR	52 Neutral	$38.62M	-0.23	-191.12%	―	―	-24.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACET	46 Neutral	$71.17M	-0.37	-71.73%	―	―	25.89%
ABVC	44 Neutral	$46.17M	-8.52	-40.32%	―	56.52%	75.22%
PLRX	42 Neutral	$72.20M	-0.41	-64.27%	―	―	14.19%

Artiva Biotherapeutics, Inc. Corporate Events

Artiva Biotherapeutics Executes RSU Exchange for Employees

On December 10-11, 2025, Artiva Biotherapeutics, Inc. executed Option for RSU Exchange Agreements with select employees, including top executives, to exchange underwater stock options for restricted stock units (RSUs) under the 2024 Equity Incentive Plan. This initiative, approved by the Board, aims to enhance employee retention and align their interests with shareholders by providing equity awards with current value and vesting terms. The RSU grants became effective on December 12, 2025, with specific vesting schedules and conditions for acceleration in case of termination or resignation.

The most recent analyst rating on (ARTV) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Artiva Biotherapeutics, Inc. stock, see the ARTV Stock Forecast page.

Artiva Biotherapeutics Reports Positive AlloNK Trial Results

On November 12, 2025, Artiva Biotherapeutics announced positive initial safety and translational data from clinical trials of AlloNK in combination with rituximab or obinutuzumab for treating autoimmune diseases. The trials demonstrated that AlloNK was well tolerated, with no serious adverse events, and showed consistent B-cell depletion, comparable to CD19-auto-CAR-T therapies. This data supports the feasibility of administering AlloNK in outpatient and community settings, potentially addressing unmet needs in refractory rheumatoid arthritis, with plans for further clinical response data and FDA interactions in 2026.

The most recent analyst rating on (ARTV) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Artiva Biotherapeutics, Inc. stock, see the ARTV Stock Forecast page.